• PLA gives overlooked biological evidence its own analysis before combining the findings.
• Published HCC research connects PLA-guided investigation with a four-gene survival signature validated in an independent patient cohort.
• As Anthropic and OpenAI expand biological discovery with AI agents, Oncotelic is targeting a 100-billion-vector protein program.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is building its PDAOAI drug discovery engine around a compelling premise: a clue buried in a small corner of the literature can redirect an entire research program. Its Partitioned Literature Aggregation (“PLA”) algorithm is designed to uncover those clues. A liver-cancer study published in Biomedicines on October 23, 2026, now provides a concrete example of that approach reaching patient-data validation.

In its October 26 announcement, Oncotelic highlighted the HCC publication and its connection to the broader PDAOAI discovery program, following the company’s October 22 keynote at the 22nd Drug Discovery Strategic Summit.

Giving the overlooked clue a chance

PLA partitions vectorized biomedical literature by disease or mechanism, analyzes each group independently, and aggregates the findings. A single similarity-ranked evidence pool can let a large research field crowd out a smaller but informative one. PLA gives those smaller bodies of evidence dedicated attention, preserving differences and exceptions that can point to a new biological question.

The platform’s intellectual-property foundation includes Oncotelic’s published international patent application WO 2025/117898 A1, Structures and methods for autonomous agents. The filing describes vector-based retrieval, separate document or fragment queries, and aggregation of the resulting responses.

PDAOAI currently indexes approximately 29 million PubMed abstracts. The opportunity is to connect evidence across that literature and turn an overlooked observation into a focused investigation.

Published HCC findings connect the method to patient outcomes

The HCC study applied PLA across 24 cancer-specific literature collections, bringing the contrast between successful mTOR-inhibitor use in renal cancer and unsuccessful historical trials in liver cancer into focus. Transcriptomic survival analysis then identified a four-gene composite: PPARGC1A, EIF4E, RRAGC, and FKBP1A.

In the discovery analysis, patients with high adverse-risk scores had a 2.59-fold higher hazard of death. The same score subsequently separated survival outcomes in an independent Japanese cohort of 203 patients, without selecting new genes or refitting its coefficients. This independently validated prognostic association provides a basis for identifying higher-risk patients and prospectively testing whether the signature can help guide mTOR-directed treatment research.

Anthropic and OpenAI reinforce the case for focused investigation

The broader AI field is producing evidence for dividing complex biological questions into focused investigations and combining the results. Oncotelic sees this convergence as independent support for the partition-and-aggregate principle behind PLA.

Anthropic’s enzyme-discovery campaign searched a database of approximately 1.94 billion protein clusters. Its agents narrowed the search, investigated individual families, and surfaced an unusual enzyme system with CRISPR-like repeats. The campaign used 949 agent sessions over 21.5 hours, with human scientists performing the laboratory follow-up. The work illustrates how targeted investigation can uncover an unexpected feature inside an enormous biological search space.

OpenAI, PerturbAI, and Scripps Research reported a complementary result on October 21. Thousands of agents examined gene disruptions in mouse-brain data, connected the results with literature, and combined their findings. At the largest tested workload, distributed agents cited more than 700 references versus 11 for a single agent under fixed model and resource conditions. In blinded comparisons, experts preferred the distributed reports 75% of the time.

The next ambition is 100 billion protein vectors

Oncotelic has announced plans to extend PDAOAI into genetic and protein discovery at a target scale of approximately 100 billion vectors. The goal is to carry focused biological investigation beyond published abstracts and into protein representations, using coordinated AI agents to pursue questions at a much larger scale.

The 100-billion figure is a development target for numerical representations of biological information. Anthropic’s 1.94-billion figure counts protein clusters, so the two describe different kinds of scale. For Oncotelic, the promise is a richer search space in which disease evidence, protein relationships, and testable hypotheses can be connected.

The strategic opportunity resembles a scientific land grab: finding valuable biological mechanisms and establishing what they can do before they are widely understood. Turning those findings into useful tools or treatments is the prize. Oncotelic enters that race with a PLA-based discovery engine, published HCC findings, and an ambitious next step. The next valuable clue may already be in the data.

For more information, visit PDAOAI.com and Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

• Autonomous drones depend on more than flight capabilities. Secure communications, reliable control systems and trustworthy data are also essential to maintaining mission success.
• As unmanned systems operate in increasingly contested environments, cybersecurity can help protect against threats ranging from unauthorized system changes to disrupted or manipulated communications.
• Mobilicom Ltd. addresses these risks through its Secured Autonomy (TM) framework, which spans platform security, communications and electronic warfare (“EW”) protection, and fleet-level security.

Autonomous drones and other unmanned systems are designed to carry out missions with varying degrees of human oversight. But their capabilities depend on more than their ability to fly or navigate. They also depend on communications links connecting platforms with operators, onboard control systems that execute mission instructions, and reliable data that supports decision-making.

These interconnected components create potential vulnerabilities. Communications can be disrupted or manipulated, software and onboard systems can be subject to unauthorized changes, and compromised data can undermine mission execution. In military environments, where drones may operate under electronic warfare pressure or face deliberate cyberattacks, these risks can have consequences beyond the individual platform.

Cybersecurity is therefore becoming an important layer of operational resilience. Although no solution can eliminate every threat, protective measures can help safeguard mission systems, strengthen communications security and reduce the risk of unauthorized access or interference.

Mobilicom Ltd. (NASDAQ: MOB), a provider of cybersecurity, software and hardware solutions for drones, robotics and autonomous platforms, addresses these challenges through its Secured Autonomy (TM) framework. The approach recognizes that protecting autonomous operations requires security across multiple interconnected layers, rather than relying on any single component.

The first pillar, Platform Security, focuses on onboard systems and mission logic. Through its OS3 cybersecurity software, Mobilicom helps protect mission computers, software and internal networks against tampering and unauthorized changes, preserving the integrity of the systems responsible for executing a mission.

The second pillar, Communications and Electronic Warfare (“EW”) Protection, focuses on links carrying control commands, telemetry and video. These connections can be vulnerable to jamming, spoofing, interception and other link-level threats. Mobilicom’s secure communications hardware and ICE software suite are designed to improve communications resilience and protect against electronic warfare threats in contested environments.

The third pillar, Fleet-Level Protection, extends cybersecurity beyond individual drones to the systems used to oversee and coordinate multiple platforms. Through OS3, Mobilicom provides cybersecurity capabilities designed to secure operational control, manage access and enforce security policies across connected fleets, addressing risks that can emerge as unmanned operations become more connected and complex.

Mobilicom also works with autonomy and technology providers to integrate its cybersecurity capabilities into broader solutions. Through these collaborations, manufacturers can incorporate protection into their platforms as they are developed and deployed, helping make cybersecurity a foundational part of autonomous-system design.

As military organizations increasingly rely on unmanned platforms, securing how drones communicate, process information and operate as part of a wider network is becoming increasingly important. Mobilicom’s Secured Autonomy (TM) framework reflects this broader approach: protecting the systems and connections that help autonomous platforms operate reliably and complete missions in challenging environments.

For more information, visit the company’s website at Mobilicom.com.

NOTE TO INVESTORS: The latest news and updates relating to MOB are available in the company’s newsroom at https://ibn.fm/MOB

Stocktoberfest presented by Tradr ETFs, Stocktwits’ flagship annual event held in New York City from October 5 to 7, was designed around a simple idea: put the right people in the same room and let the conversations happen. More than 350 ticketed guests attended, including 40 financial creators with a combined audience of more than 11 million followers.

Stocktwits built the guest list around five groups that rarely share a stage: top traders and Chartered Market Technicians; public company executives, including CEOs, CFOs, and investor relations leads; data and information providers building the infrastructure behind trading decisions; registered investment advisors and retail analysts; and the financial content creators driving retail investor engagement across social platforms and emerging financial media.

Attendees and speakers came from firms across the investing ecosystem, including Webull, Two Sigma, Cantor Fitzgerald, DraftKings, Cboe, Public, and State Street Investment Management.

The October 7 programming at City Winery reflected that mix. Brokerage and trading infrastructure leaders included Anthony Denier, US CEO of Webull; Jack Keating, CEO of Webull Tech US; and Nadia Asoyan, CFO of Alpaca. Company executives on the investor relations and small-cap panels included Phil De Sousa, CFO of Voyager Technologies; Paul Prager, Co-Founder and CEO of TeraWulf Inc.; Linda Montgomery, VP of Corporate Development at ZenaTech; and Anupam Ghildyal, CGO of REalloys.

Creators and advisors were well represented, with Chris Camillo of DumbMoney.TV, Samantha LaDuc of LaDucTrading.com, Douglas Boneparth of Bone Fide Wealth, and Gautam Shah of Eras Capital. Investment and market-structure voices included Barry Ritholtz of Ritholtz Wealth Management, Ted Seides of Capital Allocators, Ben Hunt, and Michael Parekh. Stocktwits Founder and CEO Howard Lindzon hosted throughout the day.

Many of the event’s partners did more than sponsor. Tradr ETFs, the event’s Title Partner, was represented on the Leveraged & Inverse ETFs panel by Matt Markiewicz, Head of Product and Capital Markets, alongside Bilal Little, Global ETF Strategist at fellow partner Direxion. Nasdaq Private Market COO Andrew Krochulick led a fireside chat on private markets, and Secfi CEO and Founder Frederik Mijnhardt led one on late-stage private valuations. Partners Alpaca, Voyager Technologies, ZenaTech, REalloys, and Rothschild Wealth Partners also had executives on stage.

Stocktoberfest 2026 was presented by Title Partner Tradr ETFs. Supporting partners were Nasdaq Private Market, MicroSectors, Direxion, ZenaTech, REalloys, IBN, Voyager Technologies, Secfi, and Accutron. On-site partners were Alpaca, Maxim Group, ArcStone, Carbon Arc, Lowenstein Sandler, Rothschild Wealth Partners, and VanEck.

Stocktwits thanks each partner for helping bring together the traders, creators, and executives who make the Stocktwits community what it is.

For more information and to stay tuned for Stocktoberfest 2027, visit stocktoberfest.stocktwits.com

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• The plan projects estimated net cash flow of US$1.68 billion before taxes and US$1.32 billion after taxes over an 11-year active mine life.
• Output steps up to roughly 112,500 Au Eq ounces a year from Year 4 through Year 11, with four years of the plan topping 120,000 ounces.
• Nevada accounted for about 64% of U.S. gold mine production in 2025, according to the U.S. Geological Survey.

Gold is holding over US$4,100 an ounce though mid-October, a level few mine plans were built around, but higher prices don’t produce new ounces on their own. New mines take years to permit, finance and build, and the projects best placed to benefit are those with credible production plans, defined capital requirements and economics that can withstand a retreat in metal prices. Dual-listed on the TSX Venture Exchange and OTCQB, Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) just put numbers to that case.

On October 14, 2026, the company released an updated Preliminary Economic Assessment (“PEA”) for its flagship Santa Fe Mine in Nevada’s Walker Lane. The study outlines a post-tax net present value at a 5% discount rate of US$820 million and an internal rate of return (“IRR”) of 40.1% at base-case prices of US$3,600 gold and US$49 silver. That NPV is more than fourteen times the US$56.5 million figure in the 2024 PEA, though the two studies reflect different mine plans and economic assumptions, including substantially higher metal prices in the update.

The Cash-Flow Math

The plan projects estimated net cash flow of US$1.68 billion before taxes and US$1.32 billion after taxes over an 11-year active mine life. Pre-production capital is estimated at US$172 million, including a US$22.2 million contingency, with payback projected in 3.7 years.

Estimated cash costs are US$1,909 per gold ounce and all-in sustaining costs are US$2,250. At the base-case gold price, that AISC represents a spread of US$1,350 per ounce, and higher gold prices would widen it, assuming costs hold.

A Production Profile That Builds

The operation would process 4.6 million tonnes per year (12,500 tonnes per day) for the first three years, then expand to 6.2 million tonnes per year (17,000 tonnes per day). Output climbs from roughly 23,000 gold-equivalent (Au Eq) ounces in Year 1 to nearly 48,000 in Year 3, then jumps to 122,800 ounces in Year 4 as throughput and grades step up.

Across the full plan, average annual production comes to about 91,900 Au Eq ounces, made up of roughly 88,300 ounces of gold and 254,000 ounces of silver. Output steps up to roughly 112,500 Au Eq ounces a year from Year 4 through Year 11, with four years of the plan topping 120,000 ounces.

The plan draws on four deposits (Santa Fe, Calvada, Slab and York) and, for the first time, includes sulfide material from the Santa Fe pit, which would be pre-oxidized on a separate pad before leaching.

Leverage Without Dependence

The project remains sensitive to the gold market but holds up at lower prices. At US$3,000 gold and US$30 silver, roughly 28% below the recent spot gold price, post-tax NPV comes to US$476.2 million with a 27.3% IRR. At the spot case of US$4,166 gold and US$59 silver, post-tax NPV rises to US$1.13 billion and IRR to 50.4%, with payback shortening to 3.3 years.

Why Nevada Still Anchors U.S. Gold

Nevada accounted for about 64% of U.S. gold mine production in 2025, according to the U.S. Geological Survey. The country mined an estimated 160 tonnes of gold that year, worth about US$17 billion, ranking fifth worldwide. Nevada was also the leading mineral-producing state by value for the second straight year.

That concentration reflects more than geology. Nevada has a workforce, contractors and supply chains built around open-pit, heap-leach gold mining, the same approach Santa Fe used when it produced 359,202 ounces of gold and 702,067 ounces of silver between 1988 and 1995.

Lahontan has completed its environmental baseline studies, the PEA mine plan will inform the final Mine Plan of Operations to be submitted to the U.S. Bureau of Land Management, and the company expects to obtain construction permits in 2027. With gold prices reflecting uncertainty abroad, Nevada’s established mining industry and regulatory framework provide a familiar setting for development, although Santa Fe must still secure permits, financing and construction approvals before production can resume.

The Cornerstone

Founder and CEO Kimberly Ann called Santa Fe “the cornerstone of Lahontan’s strategy to become a gold and silver producer focused on Nevada, one of the world’s premier mining jurisdictions.” The company is also drilling Santa Fe’s historic heap-leach pads and advancing the West Santa Fe satellite project roughly 13 kilometers to the southwest.

The PEA remains preliminary, includes Inferred Mineral Resources and does not establish mineral reserves or guarantee economic viability. Still, it provides a detailed framework for evaluating Santa Fe’s potential production, capital requirements and cash generation as Lahontan advances permitting.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

• Golf simulation producer TruGolf Holdings has engaged wholly owned subsidiary Polymath to migrate the capitalization table of its TruGolf Links franchise business onto Polymesh, a blockchain designed for regulated digital securities.
• The agreement marks the first internal technology deployment since TruGolf completed its acquisition of Polymath on October 8, 2026, as the combined company seeks to pair TruGolf’s established golf simulation business with Polymath’s digital securities infrastructure.
• TruGolf Links’ Regional Developers in New Jersey, New York, and Illinois represent more than 100 future locations, as the network scales toward 221+ committed locations.
• The tokenized ownership infrastructure is intended to support investor onboarding and compliance controls as the franchise network expands.
• TruGolf and Polymath are developing an equipment leasing program and fractional franchise ownership opportunities for qualified franchisees, with initial rollout targeted for the first quarter of 2027.

TruGolf Holdings (NASDAQ: TRUG), a producer of advanced golf simulation systems for home or entertainment venues, has engaged its newly acquired subsidiary Polymath to put the ownership records of its indoor golf franchise business onto a blockchain-based securities platform, marking the first technology deployment announced since TruGolf and Polymath officially combined October 8, 2026.

Under an intercompany agreement announced October 14, TruGolf Links Franchising LLC will work with Polymath Research Inc. to migrate its capitalization table, or cap table, onto Polymesh, a public, permissioned blockchain designed for regulated digital assets. The system is intended to incorporate investor identity verification and transfer restrictions into the digital representation of equity ownership (https://ibn.fm/Ikbrm).

The agreement follows TruGolf’s completion of its acquisition of Polymath on October 8. It provides an initial practical application for the tokenization business within TruGolf’s existing operations, rather than an external customer deployment.

The companies are also developing an equipment leasing program and fractional franchise ownership opportunities for qualified franchisees. Initial rollout is targeted for the first quarter of 2027.

The development links two different business models: TruGolf’s golf simulation hardware and software operations, and Polymath’s technology for issuing and managing tokenized securities. 

TruGolf Links uses a Regional Developer model in which operators acquire exclusive territories in markets with populations of one million or more. The company opened its flagship location at Plaza at Cherry Hill in New Jersey in July. TruGolf Links’ Regional Developers in New Jersey, New York, and Illinois represent more than 100 future locations, as the network scales toward 221+ committed locations. These are planned locations represented by developer commitments, not operating facilities.

As a franchise network grows, keeping ownership records accurate and managing transfers can become more complex. Polymath’s planned cap-table migration is intended to provide a centralized, real-time record of equity ownership while embedding identity checks and restrictions on transfers into the tokenization infrastructure. The structure is designed to help support compliance with applicable securities laws. 

In the company’s announcement of the engagement, TruGolf Links President Nate Larsen described the project as a next step in applying technology not only to how golf is played, but also to how the underlying business is owned. 

“TruGolf has spent more than forty years proving the game belongs indoors. Every bay we open runs on TruGolf’s trusted simulation technology. Now the business behind those bays runs on technology built for where we believe capital markets are heading. We built the future of how golf is played. This is the next chapter: how it’s owned,” Larsen said.

Natalie Hirsch, TruGolf’s chief financial officer and chief operating officer, and Polymath’s chief executive officer, characterized the deployment as an early example of pairing an operating business with digital securities infrastructure.

TruGolf has operated in golf technology for more than four decades. Its business includes indoor golf simulation systems, software and the E6 platform, which supports digital golf experiences and competition. TruGolf Links offers indoor golf facilities with memberships, leagues, lessons, tournaments and private events. Its expansion model depends on franchise development and the ability to attract operators who can finance and run additional locations.

Founded in 2017, Polymath developed the ST-20 security token standard and launched Polymesh in 2021. Its technology is designed to support the issuance and administration of digital securities, with identity and compliance functions built into the network.

For more information, visit the company’s website at www.TruGolf.com.

NOTE TO INVESTORS: The latest news and updates relating to TRUG are available in the company’s newsroom at https://ibn.fm/TRUG

Important Notice

No securities are currently being offered pursuant to this announcement. Any future offering, including any equipment leasing or fractional franchise ownership opportunity, will be made only pursuant to applicable offering documents and in accordance with applicable securities laws and regulations. This release is not an offer to sell or a solicitation of an offer to buy any security, and is not a recommendation with respect to any investment.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as forward-looking information within the meaning of applicable securities laws. Forward-looking statements are statements that are not historical facts and include statements regarding beliefs, plans, expectations, intentions, estimates, projections, or assumptions regarding future events or performance.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the services to be provided by Polymath to TruGolf Links and the anticipated benefits of the agreement; the migration of TruGolf Links’ capitalization table to tokenized form; the anticipated development and timing of TruGolf Links’ equipment leasing program and fractional franchise ownership opportunities; the expected growth of the TruGolf Links franchise network; and the anticipated benefits of TruGolf’s acquisition of Polymath.

Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “projects,” “estimates,” “may,” “will,” “would,” “could,” “should,” and similar expressions or the negative thereof. These statements are based on current expectations, assumptions, and estimates of management as of the date of this press release and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or developments to differ materially from those expressed or implied by such forward-looking statements.

Factors that could cause actual results to differ materially from those contemplated by the forward-looking statements include, among others: TruGolf’s ability to successfully integrate Polymath’s business and realize the anticipated benefits of the acquisition; TruGolf Links’ ability to open committed locations; risks related to digital assets, tokenized securities, and token-related initiatives; changes in market conditions; changes in applicable laws or regulations; competitive pressures; general economic and business conditions; and other risks and uncertainties described from time to time in TruGolf’s filings with the Securities and Exchange Commission.

Although management believes that the assumptions and expectations reflected in the forward-looking statements are reasonable as of the date hereof, no assurance can be given that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and TruGolf undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Lahontan CEO walked through the steps that keep the company’s 2027 construction target on track during recent interview.
• Lahontan recently announced a definitive agreement to acquire Emergent Metals, which would give it 100% of West Santa Fe, eliminates approximately $1.73 million in future payments, and ends 1% net smelter return royalties on West Santa Fe and 27 York claims at Santa Fe, and adds adjoining New York Canyon project.
• Permitting work has been under way for the past three and a half years and an updated preliminary economic assessment is due imminently.

A gold price above $4,100 an ounce does little for a developer that cannot say when it will build, which makes the timeline the real story for companies still short of production. Dual-listed on the TSX Venture Exchange and OTCQB, Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is telling that story with a date attached, and in a recent CEO.CA interview, founder and CEO Kimberly Ann walked through the steps that keep its 2027 construction target on track. The company is a Nevada-focused mine developer advancing four gold and silver projects in the Walker Lane, led by the planned restart of the past-producing Santa Fe Mine.

Gold is holding at historically high levels while trading well off its peak. Spot gold was at $4,183.13 an ounce in early October, after hitting what CNBC reported as a two-month low. Gold’s record remains the $5,597.23 reached on January 29, 2026, and CNBC reported that traders were pricing an 82% probability of a Federal Reserve rate increase in December.

That backdrop matters for Lahontan because of the assumptions beneath the numbers. The company’s updated mineral resource estimate (“MRE”), announced August 17, outlined 1,195,000 gold-equivalent ounces in the indicated category and 1,190,000 in the inferred category, all pit constrained, a 22% increase over the 2024 estimate. It was calculated at $3,250 gold, more than $900 below last week’s spot price. Santa Fe previously produced 359,202 ounces of gold and 702,067 ounces of silver between 1988 and 1995 from open pits with heap-leach processing.

The CEO.CA conversation opened with the transaction. On September 16, Lahontan announced a definitive agreement to acquire Emergent Metals Corp., a deal that gives it 100% of West Santa Fe, eliminates approximately $1.73 million in future payments, ends 1% net smelter return royalties on West Santa Fe and 27 York claims at Santa Fe, and adds the adjoining New York Canyon project. Completion remains subject to Emergent shareholders, with a vote expected in November, court and TSX Venture Exchange approvals.

“We are looking at strategic opportunities to grow our land package on a low-cost basis,” Ann stated. “This transaction is about 4% dilution to our shareholders,” observing that the ground around the company’s existing pits drove the timing. “My team has found so much more mineralization that it was going to be problematic later and needing a layback for those pits,” she continued. “So, I wanted to pull the trigger earlier than later.”

Regarding permitting, Ann said the work has been under way for three and a half years and that an updated preliminary economic assessment is due “in the next couple weeks.” She described it as an engineering document not a promotional one, looking at “where are we putting the pads? How much dust we’re kicking up? How much rock we’re moving?”  Those details are required, she explained, “because it’s the last component of our application for a mine permit . . . [which] will set us up for having our permit in Q2 of next year.” Lahontan’s website lists Nevada state permitting as in progress, a federal Mine Plan of Operations as the next step and construction targeted for 2027.

At West Santa Fe, where Lahontan mobilized a drill rig last month for approximately 3,500 meters of drilling in 20 holes, Ann said the appeal is simple: “It’s all oxide. It starts at the surface. It’s 13 kilometers away.” She outlined two options, trucking material to Santa Fe for crushing and processing with “virtually no capex” or adding leach pads on site if drilling outlines enough ounces. Baseline studies began about nine months ago, she noted, “because we know it’s going to take two years in baseline studies.” The company is targeting a maiden resource by year-end.

Ann also addressed the build. Lahontan recently added a vice president of exploration, a senior mine engineer and an investor relations and business development lead, and named a new chief financial officer. The 2024 economic study estimated preproduction capital at $135.1 million, including a 20% contingency, and Ann said she does not expect the updated figure to rise much. The company plans to fund roughly 80% with debt and the rest with equity. “A straight debt deal is really advantageous when your payback is less than a year and a half,” she observed.

“Next year we’re going to be pouring gold,” Ann continued, adding that the company will tell investors if a timeline changes. “I like full transparency to shareholders because nobody likes it when they hear silence for six months,” she said.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax Minerals, focused on rare earth element projects in North America, has entered into a three-year option agreement to acquire a 100% interest in the Melba North Property
• The property is underlain by the Clay-Howells Alkalic Rock Complex that is interpreted as a center characterized by LREE-dominant, magnetite-associated and carbonatite-related REE mineralization
• A 2025 assessment report on the Clay-Howells claim, which included claims listed on the Melba North option schedule, documented 49 samples that returned more than 0.17% total rare earth element oxides (“TREO”)
• The Melba North Property is adjacent to Powermax’s Hopkins REE property, where the company has, using a desktop study, identified priority areas for future field validation; however, mineralization continuity between the two sites has not yet been established

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth element projects in North America, recently entered into a three-year option agreement with Gravel Ridge Resources Ltd. and 1544230 Ontario Inc. The agreement grants Powermax an option to acquire a 100% interest in the Melba North property (https://ibn.fm/YvKri).

Located in the Clay-Howells townships area of northern Ontario, the Melba North Property is adjacent to Powermax’s Hopkins REE property. It consists of 10 unpatented mining claims comprising 160 cells and covering approximately 3,360 hectares. Both the Melba North and the Hopkins are underlain by the Clay-Howells Alkalic Rock Complex, a Late Precambrian alkalic intrusive complex. Interpretations of data from the complex describe a structurally emplaced, multi-phase alkaline-carbonatite intrusive center characterized by LREE-dominant, magnetite-associated and carbonatite-related REE mineralization (https://ibn.fm/2ai8M). (Note: Although Hopkins and Melba North are adjacent sites, mineralization continuity between them has not yet been established.)

Claims listed in the Melba North option schedule were covered in a November 2025 assessment work report by Laurentia Exploration Inc. for Argyle Resources Corp. The report documented seven heli-portable BTW size drill holes totaling 1,983 meters on the Clay-Howells claim. “Across the selected samples reported, 49 returned more than 0.17% TREO (total rare earth element oxides), including 20 above 0.30% TREO and six above 0.50% TREO. The highest reported sample interval was 0.76% TREO over 0.60 m,” reads Powermax’s announcement of the agreement.

The company plans to include Melba North in its current Hopkins-area exploration work and wants to confirm whether a permit issued on September 2, 2025, remains valid and covers the planned drilling before mobilization. In addition to combining the exploration work at the two adjacent properties, Powermax intends to integrate the historical drill database with mapping, sampling, and geophysical data to “refine targets and assess follow-up drilling.”

“Melba North adds an important land position beside Hopkins and lets us evaluate the two areas within a coordinated exploration framework,” commented Paul Gorman, CEO of Powermax. “We will integrate the 2025 drilling data with our current field work and evaluate suitable targets for follow-up drilling, subject to permit conditions and regulatory approvals.”

The Melba North Property option agreement comes a few months after Powermax announced the option to acquire the Hopkins Rare Earths Project comprising 13 mineral claims that cover about 6,145 hectares (https://ibn.fm/DgcrA). The company later announced it had received a desktop study for the project, which evaluated publicly available datasets to assess REE prospectivity. The study identified multiple priority targets, providing Powermax with a clear, focused path forward for field validation (https://ibn.fm/2ai8M).

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

• Versus Systems is a leading provider of gamification and audience engagement technology, with a product ecosystem that includes games, digital platforms, and physical collectibles.
• The company enhances how audiences interact with content both physically and digitally, and lets brands, teams, and creators add interactive and engaging elements directly into fan experiences.
• Versus Systems has worked with significant brands such as the NFL, NHL, FIFA, MLS, and UFC, engaging more than 10 million customers.

Gaining consumer and viewer attention is growing more difficult than ever due to increasingly crowded digital and physical advertising landscapes. Even if a brand is able to capture attention, holding onto it is a recognized challenge.

Versus Systems (NASDAQ: VS) uses a unique and effective approach to address this issue, using gamification and powerful audience engagement strategies to maximize how audiences interact with content both on their devices and in person. The company operates a platform that lets brands, sports teams, content creators, and other businesses, put games and real-world rewards inside their content to help turn passive viewers into active participants. Versus Systems also has a patented earned-rewards system that operates across web, mobile, and in-venue formats, and supports both measurable brand interaction and audience participation, without requiring significant development.

Versus’ product ecosystem is designed to integrate gamification, rewards, and engagement, and includes Winfinite, Filter Fan Cam, and Drinkfinger.

Winfinite is Versus’ core gamified marketing platform, which offers a library of customized web-based games that you can deploy across your digital channels or add into your live events. The available options include sports, trivia, arcade, and puzzle games, and they’re designed to be broadly accessible and encourage repeat participation.

Filter Fan Cam is an in-venue AR fan engagement product that lets people in the audience of your event see themselves on the big screen with real-time visual enhancements like filters and overlays. The product is custom-built to leverage facial recognition technology, and applies filters and/or overlays over camera footage to create fun and interactive moments. These moments may be displayed in the venue itself, or even included in coverage of the event.

Versus has also partnered with Drinkfinger, an independent company that offers QR-enabled and collectible beverage carriers. The carriers, sporting an iconic “#1” finger shape, not only make it easier to transport drinks, but also puts branded designs right into a fan’s hand. Through Drinkfinger, fans can scan a QR code on a beverage carrier to access games, promotional offers, and event-related content on their phones.

Versus Systems’ products have been used across global markets, including the UK, Mexico, Japan, and others, and it has worked with major brands like the NFL, NHL, MLS, FIFA, and the UFC. It has also engaged more than 10 million customers and deployed its technology across thousands of events.

The team at Versus Systems is made up of executives with decades of experience in finance, media, technology, and led by CEO Luis Goldner and CFO Brian Goldenberg, C.P.A. Goldner brings over 16 years of executive management experience across the tech, media, and gaming industries, and Goldenberg has more than 25 years of financial and operational leadership experience, and has served as CFO, COO, and CCO at multiple investment management firms.

About Versus Systems Inc. (NASDAQ: VS)

Versus Systems is a technology company that looks to enhance how audiences interact with brands and engage with content in both digital and physical environments by using audience engagement and gamification. It lets brands, sports teams, creators, and other businesses add interactive elements into their content and experiences, and is trusted by many of the world’s leading brands.

For more information, visit the Versus Systems website at https://www.versussystems.com.

NOTE TO INVESTORS: The latest news and updates relating to VS are available in the company’s newsroom at https://ibn.fm/VSI

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertisements.

• Adaptogenics is pursuing three complementary opportunities across pharmaceutical-quality peptide supply, proprietary therapeutics and next-generation delivery technologies.
• Its planned supply network could generate commercial revenue while supporting therapeutic development through external manufacturing and laboratory partners.
• The company is targeting metabolic health, muscle preservation, mitochondrial function, recovery and healthy ageing through proprietary peptide and small-molecule therapeutics.
• CEO Dr. J. David Warren brings a scientific record that includes 17 issued patents, while President Antoun Nabhan brings experience spanning more than $2 billion in healthcare transactions and two Nasdaq IPO processes.
• Adaptogenics is evaluating non-injectable and targeted local delivery technologies that could improve peptide utility, generate intellectual property and expand commercial applications.

Adaptogenics (CSE: ADPT) is building a healthcare company focused on opportunities across the rapidly evolving peptide sector, combining proprietary therapeutic development, pharmaceutical-quality supply infrastructure and innovative drug delivery technologies.

As demand for solutions addressing metabolic health, muscle preservation, recovery and healthy ageing continues to grow, Adaptogenics is positioning itself to address significant healthcare challenges while pursuing opportunities in the expanding market for high-quality peptide development and supply.

The company’s strategy combines experienced pharmaceutical leadership, scientific innovation and a capital-efficient business model designed to create both near-term commercial opportunities and long-term value through proprietary therapeutic assets.

Three Opportunities Driving Adaptogenics’ Strategy

1. Pharmaceutical-Quality Peptide Supply

The growing interest in peptide-based healthcare is creating opportunities for reliable manufacturing, independent quality verification and transparent supply chains.

Adaptogenics is working toward establishing a U.S.-based GMP manufacturing and independently verified peptide supply network, supported by qualified manufacturing partners, analytical laboratories and documented chain-of-custody procedures.

The company’s objective is to develop a trusted supply model that can serve appropriate research, pharmaceutical and healthcare customers, subject to applicable regulatory requirements.

Rather than investing heavily in manufacturing facilities, Adaptogenics intends to leverage qualified external partners while building its own standards, development capabilities and commercial relationships.

This strategy could establish a foundation for future commercial revenue while supporting the company’s proprietary therapeutic development programs.

2. Proprietary Peptide and Small Molecule Therapeutics

Adaptogenics is pursuing the development of proprietary peptide and small molecule therapeutics targeting some of the most important challenges in modern healthcare.

Key areas of scientific and commercial interest include:

• Metabolic Health: Exploring therapeutic approaches relevant to obesity, metabolic dysfunction and the growing use of GLP-1 treatments.
• Muscle Preservation and Physical Function: Pursuing opportunities to address muscle loss, reduced strength and functional decline associated with ageing and metabolic conditions.
• Mitochondrial Health: Investigating peptide approaches targeting cellular energy and mitochondrial function.
• Recovery and Tissue Repair: Evaluating therapeutic candidates and delivery strategies that could address limitations in existing approaches to healing and recovery.
• Healthy Ageing: Exploring opportunities to preserve physical function and improve health outcomes as populations age.

The company’s objective is to generate differentiated intellectual property, advance promising candidates through meaningful scientific milestones and establish opportunities for future pharmaceutical partnerships, licensing and commercialization.

3. Next-Generation Peptide Delivery Technologies

Many peptide therapeutics face challenges related to administration, stability and absorption.

Adaptogenics is evaluating delivery technologies designed to address these limitations, including non-injectable approaches and targeted local delivery systems.

Successful development could improve the potential utility of selected peptide therapeutics, create additional intellectual property and expand their commercial applications.

The company’s approach is to select delivery technologies based on measurable performance advantages rather than pursuing a single delivery method across every molecule.

Leadership Built for Execution

Dr. J. David Warren, PhD – Chief Executive Officer

Dr. Warren is an accomplished medicinal and peptide chemist with extensive experience in therapeutic research and development.

His scientific background includes:

• 17 issued U.S. and international patents.
• More than 53 scientific publications and book chapters.
• Research experience at Weill Cornell Medicine.
• Foundational research involving the mitochondrial peptide SS-31 and its interaction with cardiolipin.

SS-31 was subsequently developed as elamipretide, marketed as Forzinity, which received FDA accelerated approval in 2025 for Barth syndrome. The product was developed by another company and is not an Adaptogenics asset.

Dr. Warren’s expertise in peptide chemistry, molecular design and drug development provides scientific leadership for Adaptogenics’ therapeutic development strategy.

Antoun Nabhan – President

Mr. Nabhan brings extensive healthcare transaction, financing and corporate development experience to Adaptogenics.

His background includes:

• More than US$2 billion in healthcare transactions.
• Experience supporting two Nasdaq IPO processes.
• Senior leadership and corporate development experience across pharmaceutical and biotechnology companies.
• Experience identifying, financing and advancing healthcare opportunities.

His expertise supports the company’s strategic partnerships, capital formation and long-term corporate development objectives.

Building Momentum

Adaptogenics is entering an important phase of its corporate development, with a strategy focused on advancing proprietary therapeutics, establishing pharmaceutical-quality supply capabilities and building a foundation for commercial growth.

Key priorities and anticipated milestones include:

• U.S. Pharmaceutical-Quality Supply: Establishing a U.S.-based GMP manufacturing and independently verified peptide supply network, creating a foundation for potential commercial opportunities and strategic healthcare partnerships.
• Proprietary Therapeutic Pipeline: Advancing peptide and small molecule development programs targeting high-value opportunities in metabolic health, muscle preservation, recovery and healthy ageing.
• Next-Generation Delivery: Progressing formulation and delivery research aimed at overcoming limitations in peptide administration, stability and bioavailability.
• Scientific Validation and Intellectual Property: Generating experimental data, advancing proprietary molecular designs and identifying opportunities to strengthen patent protection.
• Commercial Expansion: Developing relationships with healthcare providers, pharmacies and strategic distribution partners to identify compliant routes to market.
• Strategic Growth and Capital Markets: Building institutional relationships and positioning the company for its next phase of development and potential growth financing.

Together, these initiatives are intended to position Adaptogenics to advance from foundational research and infrastructure development toward proprietary therapeutic assets, potential commercial opportunities and measurable value creation.

The Long-Term Vision

Adaptogenics aims to build a substantial healthcare company operating across complementary segments of the peptide industry.

The company’s long-term vision combines:

• Commercial Opportunity: Establishing pharmaceutical-quality peptide supply capabilities and healthcare distribution relationships that could support future revenue generation.
• Scientific Innovation: Developing proprietary peptide and small molecule therapeutics addressing significant healthcare needs.
• Intellectual Property: Creating and securing differentiated molecular, formulation and delivery technologies with potential commercial value.
• Strategic Partnerships: Working with pharmaceutical companies, research institutions, qualified manufacturers and healthcare organizations to accelerate development and expand market opportunities.
• Scalable Growth: Building a capital-efficient business that can expand its therapeutic portfolio and commercial capabilities without requiring ownership of every manufacturing or research facility.

Adaptogenics believes the convergence of peptide innovation, advances in metabolic medicine and growing global demand for healthier ageing creates an opportunity for companies capable of combining scientific expertise with pharmaceutical-quality development and commercial execution.

The company’s ambition is to participate in this evolving healthcare landscape by building proprietary assets, advancing innovative therapies and establishing the infrastructure to support long-term growth.

NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT

• Orthopedic care is increasingly focused not only on relieving symptoms, but on delivering durable outcomes that can stand up over time.
• That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury.
• Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee.

Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time?

That question is particularly important in cartilage repair. Unlike many other tissues, cartilage has limited natural capacity to heal itself. The goal is to create an environment where damaged tissue can be repaired in a way that delivers meaningful and sustained results.

This emphasis on durability is helping drive interest in regenerative medicine, including approaches designed to replace damaged tissue with newly regenerated tissue rather than relying solely on temporary symptom management.

One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is built around the Gelrin platform, which uses degradable hydrogel implants to support the body’s natural regenerative processes.

The company’s lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured as a temporary implant into the knee. Rather than remaining permanently in the body, GelrinC gradually resorbs. As it retreats, newly generated cartilage fills the space, creating a controlled process intended to restore the damaged area with new tissue.

According to Regentis, the implant is designed to be fully resorbed within approximately six to nine months, at which point new cartilage has covered the treated lesion.

The procedure is also designed with practicality in mind. Regentis says GelrinC can be implanted in approximately 10 minutes, fits into existing surgical workflows and is associated with a short recovery period of approximately two weeks. Its off-the-shelf design is intended to further simplify adoption while potentially offering a substantial cost advantage compared with certain alternative treatments.

Importantly, GelrinC has already achieved a CE mark in Europe, giving Regentis a commercial pathway in that market while the company continues advancing the product in the United States.

Regentis has conducted a Pilot/Phase II study of GelrinC, with results indicating 100% greater pain improvement compared with the traditional microfracture procedure. The company is now conducting its U.S. pivotal Phase III clinical study while preparing for the Premarket Approval (“PMA”) process with the U.S. Food and Drug Administration.

Durability is also something Regentis measures directly. To assess the quality of the cartilage GelrinC helps regenerate, the company uses MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), a validated MRI-based score that evaluates the quantity and quality of repair tissue. Regentis says it is the first company to extensively use MOCART as an endpoint in a clinical study and to have the FDA’s acceptance of this approach. Long-term follow-up results from the Phase II study, published in the peer-reviewed journal Cartilage, showed a mean MOCART score of 88.8 out of 100 at 24 months, including 86.8 for chondral lesions and 94.1 for osteochondral lesions. According to the company, the data indicate that two years after treatment, the repaired cartilage appears very close to normal healthy cartilage.

That clinical progress is unfolding alongside an expanding commercialization effort. In a recent BioMedWire podcast appearance, Regentis CEO Dr. Ehud Geller discussed the company’s technology, market opportunity and priorities for the remainder of 2026.

Among those priorities is completing enrollment of the remaining patients in the company’s pivotal U.S. study while continuing to advance commercialization efforts, particularly in Europe, where Regentis already has authorization to market and sell GelrinC(R).

Those milestones provide an important backdrop to the company’s larger vision. Regentis is not simply seeking to develop another way of treating knee cartilage damage; it is pursuing a regenerative approach built around the idea that the quality of a repair should ultimately be measured by how well it lasts.

As orthopedic medicine continues to evolve, that may prove to be one of the most important measures of progress: not simply whether a treatment can provide relief today, but whether it can help patients maintain that improvement well into the future.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer